The concern of generic competition has consistently loomed around copyright’s blockbuster drug, Viagra, sparking questions about the prospects of similar drug holdings. While early times saw substantial gains, the exclusivity lapse has allowed the door for discounted alternatives, potentially diminishing profitability and creating a genuine dange